EFG
RXRX icon

Ethos Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Ethos Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.6K Sell
20,398
-3,088
-13% -$10.3K ﹤0.01% 622
2026
Q1 		$72.1K Buy
23,486
+10,466
+80% +$40.4K 0.01% 525
2025
Q4 		$53.3K Buy
+13,020
New +$64.5K ﹤0.01% 515

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ethos Financial Group's RXRX Position: Q2 2026 in Review

Ethos Financial Group reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, selling an estimated $10.3K and leaving 20,398 shares worth $60.6K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

Ethos Financial Group first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $72.1K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Ethos Financial Group held 20,398 shares of Recursion Pharmaceuticals worth $60.6K as of Q2 2026.
  • Ethos Financial Group sold 3,088 Recursion Pharmaceuticals shares in Q2 2026, an estimated $10.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Ethos Financial Group's portfolio in Q2 2026, its #622 holding.
  • Ethos Financial Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ethos Financial Group's Recursion Pharmaceuticals position peaked at $72.1K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.